Gautron Moura, B.; Gerard, C.L.; Testart, N.; Caikovski, M.; Wicky, A.; Aedo-Lopez, V.; Berthod, G.; Homicsko, K.; Prior, J.O.; Dromain, C.;
et al. Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers 2023, 15, 31.
https://doi.org/10.3390/cancers15010031
AMA Style
Gautron Moura B, Gerard CL, Testart N, Caikovski M, Wicky A, Aedo-Lopez V, Berthod G, Homicsko K, Prior JO, Dromain C,
et al. Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers. 2023; 15(1):31.
https://doi.org/10.3390/cancers15010031
Chicago/Turabian Style
Gautron Moura, Bianca, Camille L. Gerard, Nathalie Testart, Marian Caikovski, Alexandre Wicky, Veronica Aedo-Lopez, Grégoire Berthod, Krisztian Homicsko, John O. Prior, Clarisse Dromain,
and et al. 2023. "Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma" Cancers 15, no. 1: 31.
https://doi.org/10.3390/cancers15010031
APA Style
Gautron Moura, B., Gerard, C. L., Testart, N., Caikovski, M., Wicky, A., Aedo-Lopez, V., Berthod, G., Homicsko, K., Prior, J. O., Dromain, C., Kandalaft, L. E., Cuendet, M. A., & Michielin, O.
(2023). Estimated Costs of the Ipilimumab–Nivolumab Therapy and Related Adverse Events in Metastatic Melanoma. Cancers, 15(1), 31.
https://doi.org/10.3390/cancers15010031